Navigation Links
Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung
Date:7/13/2014

amm in Japan unterstützt.  

Im Mai vergangenen Jahres ging Astellas eine strategische Allianz mit Amgen ein, um insgesamt fünf Medikamente aus der Amgen-Pipeline zu entwickeln und in Japan zu vermarkten. Im Rahmen der Tagung wurden die aktuellen Entwicklungsergebnisse von drei dieser Produkte thematisiert, darunter Rilotumumab (AMG 102) zur Behandlung von Magenkrebs, Evolocumab (AMG 145) zur Behandlung von Hyperlipidämie sowie Romosozumab (AMG 785) zur Behandlung von Osteoporose.  

"Unsere fortgeschrittene Pipeline ist stabil und eng mit unserer Vermarktungsstrategie verbunden," erklärte Ken Jones, Firmenchef und CEO von Astellas Pharma EMEA. "In Europa zählt die F&E zu den wichtigsten Prioritäten. In unserem Arzneimittel-Entwicklungszentrum in den Niederlanden arbeiten Wissenschaftler aus über 30 Ländern. Die hier vor Ort und in aller Welt umgesetzten Forschungsmaßnahmen tragen zur Entwicklung einer Vielzahl verschiedener Prüfpräparate bei, die das kontinuierliche Wachstum des Unternehmens in der EMEA-Region und auf globaler Ebene begünstigen werden."

"Durch effiziente Investitionen in die F&E bietet Astellas seinen Aktionären bereits seit geraumer Zeit Mehrwerte. Diese Investition hat zu zahlreichen bedeutenden neuen Behandlungsoptionen geführt, mit deren Hilfe wir unerfüllten medizinischen Bedürfnissen von Patienten entsprechen konnten", so Kurstjens. "Aufgrund unserer Bemühungen haben wir nun die GCL-Stellung (Global Category Leadership) in den Bereichen Urologie und Transplantation und eine aufstrebende GCL-Stellung im Bereich der Onkologie inne. Wir sind mit den Fortschritten unserer Pipeline in diesen Behandlungskategorien sehr zufrieden und sehen unserem künftigen Vorhaben, unsere F&E-Bemühungen zur Er
'/>"/>

SOURCE Astellas Pharma Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
2. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
3. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
5. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
6. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
7. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
8. Astellas to Drive PGA TOURs New Womens Initiative
9. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
10. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
11. Astellas Pharma Inc.: New Hire Reinforces Global Compliance Structure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014 Research ... "Stem Cell Research Products: Opportunities, Tools & Technologies" ... already supply stem cell research products or you wish ... essential and lucrative this market is. The authors know ... sell more effectively to scientists, to generate improved revenues ...
(Date:8/22/2014)... CHICAGO , Aug. 22, 2014   Zacks Equity Research ... the Bull of the Day and Panera (Nasdaq: PNRA - ... Zacks Equity Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD ... ) and Shire (Nasdaq: SHPG - Free Report ). ... Bull of the Day : The ...
(Date:8/22/2014)... 2014  - MediaLINC ... Today Lincor announced general availability of MediaLINC ... a range of education, entertainment and clinical content direct ... http://photos.prnewswire.com/prnh/20140822/702945) , " Lincor has ... patient engagement to bedside smart devices, " comments ...
Breaking Medicine Technology:Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 2Global Stem Cell Research Products: Opportunities, Tools & Technologies - 2014 Report 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Lincor Unveils Next Generation TV-based Patient Engagement Solution 2
... QTinno(TM) - proves the ability to automatically measure QT ... intervals in even challenging samples, ... Board: NWCI) a cardiac diagnostic and services company, today,revealed the ... Study"). The study was led by an independent industry leading,cardiac ...
... Battles Highest Rate of TB Infection in U.S., ... highest,rate of tuberculosis (TB) in the U.S., with recurrent ... most recent study on,homelessness and TB by Harvard Medical ... in San Francisco. To address this health care,crisis, St. ...
Cached Medicine Technology:NewCardio Announces Positive Results From Third Clinical Validation Study 2NewCardio Announces Positive Results From Third Clinical Validation Study 3NewCardio Announces Positive Results From Third Clinical Validation Study 4NewCardio Announces Positive Results From Third Clinical Validation Study 5National Healthcare for Homeless Day: August 13th, 2008 2
(Date:8/22/2014)... UT (PRWEB) August 22, 2014 Today, ... a new guide on Account-Based Health Plans. , According ... (ABHPs) as a strategy to lower the cost of ... types of medical spending accounts, however, can be confusing. ... chart to learn the four main types of ABHPs. ...
(Date:8/22/2014)... August 23, 2014 Top 10 ... famous web hosting companies and highly recommended FatCow ... , The manager of Top 10 Best SEO ... good dedicated server hosting supplier. Actually, these companies ... server speed and customer support. People can get ...
(Date:8/22/2014)... Recently, UWDress.com, a leading online supplier of ... new range of empire bridesmaid dresses to its ... a summer promotion for these high quality items. All of ... to 75 percent off. , The company’s new items ... efficient assistance on its website. It is true that all ...
(Date:8/22/2014)... 2014 Buying a policy for different life ... unsure about available coverage types by insurers in the U.S. ... policy pricing to the public using its sortable tool at ... is free and is expected to promote the discounts and ... throughout the U.S. The system is designed to help an ...
(Date:8/22/2014)... Japantown Dental is excited to announce that ... Air polishing is a technique used to remove external ... be caused by a number of factors, which are ... External stains include coffee, wine, tea, smoking and chewing ... such as tetracycline, and direct trauma to the tooth. ...
Breaking Medicine News(10 mins):Health News:FatCow Reviews Released by Top10BestSEOHosting.com 2Health News:Discounted Empire Bridesmaid Dresses Online At UWDress.com 2Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Japantown Dental Introduces Air Polishing 2
... ROCHESTER, N.Y., Nov. 26 As one of the ... considering the most sweeping,changes to that state,s health care ... the Christian Science church, called on,state leaders to bring ... access to effective health care by including spiritual,care., ...
... The Wackenhut,Corporation, the leading security services provider, announced ... its employee medical and dental,insurance plans significantly for ... that Wackenhut,s focus on employee welfare is a,primary ... Mercer, released an overview of,its most recent annual ...
... FLEX ),today announced that it will report third quarter ... call, hosted by Flextronics,s senior,management, will be held at ... Company for its third quarter ended December 31, 2007., ... Internet and may be,accessed by logging on to the ...
... with the devices aren,t prone to accidents , , MONDAY, ... implanted in people for instant correction of abnormal heartbeats ... researchers report. , "What this confirms is what we ... risk in this population," said study lead author Dr. ...
... Agreement will Broaden Access to ... Cholesterol-Reducing Medicine, PHILADELPHIA and ... and Merck & Co., Inc.,Whitehouse Station, NJ, USA (Merck), announced ... marketing rights for,MEVACOR(R) (lovastatin). Under the agreement, GSK will have ...
... Older and newer medicine together often bring relief, study ... an older synthetic drug with a newer, "biologic" medication ... tenderness of rheumatoid arthritis, a new study finds. , ... newer drugs are not better than older ones when ...
Cached Medicine News:Health News:Wackenhut Enhances Health Insurance Plans Without Raising Costs 2Health News:Flextronics to Report Third Quarter Results 2Health News:Defibrillators Not Dangerous While Driving 2Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 2Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 3Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 4Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 5Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 6Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 7Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 8Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 9Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 10Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 11Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 12Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 13Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 14Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 15Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 16Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 17Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 18Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 19Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 20Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 21Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 22Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 23Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 24Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 25Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 26Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 27Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 28Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 29Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 30Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 31Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 32Health News:GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc. 33
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: